BiotechTube

ARCT-2303 + Influenza vaccine + Influenza vaccine, adjuvanted

Phase 3Completed
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

COVID-19

Conditions

COVID-19

Trial Timeline

Mar 27, 2024 → Nov 21, 2024

NCT ID
NCT06279871

About ARCT-2303 + Influenza vaccine + Influenza vaccine, adjuvanted

ARCT-2303 + Influenza vaccine + Influenza vaccine, adjuvanted is a phase 3 stage product being developed by Arcturus Therapeutics for COVID-19. The current trial status is completed. This product is registered under clinical trial identifier NCT06279871. Target conditions include COVID-19.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06279871Phase 3Completed

Competing Products

20 competing products in COVID-19

See all competitors
ProductCompanyStageHype Score
Human COVID-19 immunoglobulin (pH4) for intravenous injection + PlaceboSinopharmPhase 2
51
Mavrilimumab + PlacebosKiniksa PharmaceuticalsPhase 2
47
Gimsilumab + PlaceboRoivant SciencesPhase 2
49
Icosapent ethylAmarin CorporationPhase 2
44
Bamlanivimab + Placebo + EtesevimabEli LillyPhase 3
77
InfliximabCelltrionPhase 2
52
CT-P63 and CT-P66 / PlaceboCelltrionPhase 3
77
Enzalutamide PillAstellas PharmaPhase 2
52
S-892216 + PlaceboShionogiPhase 2
52
S-892216 + CarbamazepineShionogiPhase 1
33
FOY-305 + PlaceboOno PharmaceuticalPhase 3
77
DesidustatZydus LifesciencesPhase 2
52
LY3819253 + PlaceboEli LillyPhase 1
33
Bamlanivimab + Etesevimab + Placebo + VIR-7831 + BebtelovimabEli LillyPhase 2
52
BamlanivimabEli LillyPhase 2
52
LY3127804 + PlaceboEli LillyPhase 2
52
Baricitinib + PlaceboEli LillyPhase 3
77
BamlanivimabEli LillyPre-clinical
23
LY3819253 + Placebo + RemdesivirEli LillyPhase 3
77
LY3819253 + LY3832479 + LY3853113 + PlaceboEli LillyPhase 2/3
65

Other Products from Arcturus Therapeutics

ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine + Astra Zeneca COVID-19 vaccinePhase 2/3
57
ARCT-032Phase 2
44
ARCT-810Phase 2
44
ARCT-021 single dose priming + ARCT-021 two lower dose priming + ARCT-021 two higher dose priming + Placebo (two doses), priming + Randomized booster + Placebo boosterPhase 2
44
SARS-CoV-2 mRNA Vaccine ARCT-021 + TozinameranPhase 2
44